Refractory patients with favorable/intermediate‐risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation

Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML

(2021) Firas El Chaer et al.   Blood Advances

Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia

(2020) Naveed Ali et al.   LEUKEMIA & LYMPHOMA

A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance)

(2019) Ravi Vij et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia

(2018) C. Craddock et al.   JOURNAL OF INTERNAL MEDICINE

Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies

(2018) Kathryn T. Maples et al.   LEUKEMIA & LYMPHOMA

Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial

(2016) Charles Craddock et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study

(2015) Nelli Bejanyan et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION